Applications of Human Pharmacokinetic Prediction in First-in-Human Dose Estimation

被引:92
|
作者
Zou, Peng [3 ]
Yu, Yanke [3 ]
Zheng, Nan [3 ]
Yang, Yongsheng [2 ]
Paholak, Hayley J. [3 ]
Yu, Lawrence X. [1 ]
Sun, Duxin [3 ]
机构
[1] US FDA, Ctr Drug Evaluat & Res, Off Gener Drugs, Rockville, MD 20857 USA
[2] US FDA, Ctr Drug Evaluat & Res, Off Testing & Res, Silver Spring, MD 20993 USA
[3] Univ Michigan, Coll Pharm, Dept Pharmaceut Sci, Ann Arbor, MI 48109 USA
来源
AAPS JOURNAL | 2012年 / 14卷 / 02期
基金
美国国家卫生研究院;
关键词
allometric scaling; FIH dose; in vitro-in vivo correlations; pharmacokinetics; prediction; HUMAN DRUG CLEARANCE; HEPATIC METABOLIC-CLEARANCE; IN-VITRO DATA; CRYOPRESERVED HUMAN HEPATOCYTES; HUMAN LIVER-MICROSOMES; HUMAN ORAL BIOAVAILABILITY; MEMBRANE PERMEATION ASSAY; INTRINSIC CLEARANCE; PHASE-I; VERTICAL ALLOMETRY;
D O I
10.1208/s12248-012-9332-y
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Quantitative estimations of first-in-human (FIH) doses are critical for phase I clinical trials in drug development. Human pharmacokinetic (PK) prediction methods have been developed to project the human clearance (CL) and bioavailability with reasonable accuracy, which facilitates estimation of a safe yet efficacious FIH dose. However, the FIH dose estimation is still very challenging and complex. The aim of this article is to review the common approaches for FIH dose estimation with an emphasis on PK-guided estimation. We discuss 5 methods for FIH dose estimation, 17 approaches for the prediction of human CL, 6 methods for the prediction of bioavailability, and 3 tools for the prediction of PK profiles. This review may serve as a practical protocol for PK- or pharmacokinetic/pharmacodynamic-guided estimation of the FIH dose.
引用
收藏
页码:262 / 281
页数:20
相关论文
共 50 条
  • [21] Pharmacokinetic/pharmacodynamic modeling for dose selection for the first-in-human trial of the activated Factor XII inhibitor garadacimab (CSL312)
    Pawaskar, Dipti
    Chen, Xi
    Glassman, Fiona
    May, Frauke
    Roberts, Anthony
    Biondo, Mark
    McKenzie, Andrew
    Nolte, Marc W.
    Jusko, William J.
    Tortorici, Michael
    CTS-CLINICAL AND TRANSLATIONAL SCIENCE, 2022, 15 (03): : 709 - 720
  • [22] Prediction of Exposure–Response Relationships to Support First-in-Human Study Design
    John P. Gibbs
    The AAPS Journal, 2010, 12 : 750 - 758
  • [23] Using Mitra sampling to support first-in-human pharmacokinetic evaluations for PF-07059013
    Lee, Kimberly C.
    Wan, Katty X.
    Barricklow, Jason
    Lim, Chay Ngee
    Clarke, Stephen
    Potts, Daniel
    Holmes, Kevin
    Gonzalez, Pilar
    Kavetska, Olga
    BIOANALYSIS, 2023, 15 (17) : 1083 - 1094
  • [24] A Pilot, First-in-Human, Pharmacokinetic Study of 9cUAB30 in Healthy Volunteers
    Kolesar, Jill M.
    Hoel, Ryan
    Pomplun, Marcia
    Havighurst, Tom
    Stublaski, Jeanne
    Wollmer, Barbara
    Krontiras, Helen
    Brouillette, Wayne
    Muccio, Donald
    Kim, KyungMann
    Grubbs, Clinton J.
    Bailey, Howard E.
    CANCER PREVENTION RESEARCH, 2010, 3 (12) : 1565 - 1570
  • [25] A PBPK workflow for first-in-human dose selection of a subcutaneously administered pegylated peptide
    Offman, Elliot
    Edginton, Andrea N.
    JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS, 2015, 42 (02) : 135 - 150
  • [26] First-in-Human Dose Selection for T-Cell Engaging Bispecific Antibodies
    van Der Graaf, Piet H.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2025, 117 (01) : 11 - 13
  • [27] A PBPK workflow for first-in-human dose selection of a subcutaneously administered pegylated peptide
    Elliot Offman
    Andrea N. Edginton
    Journal of Pharmacokinetics and Pharmacodynamics, 2015, 42 : 135 - 150
  • [28] Practical approaches to dose selection for first-in-human clinical trials with novel biopharmaceuticals
    Tibbitts, Jay
    Cavagnaro, Joy A.
    Haller, Christine A.
    Marafino, Ben
    Andrews, Paul A.
    Sullivan, John T.
    REGULATORY TOXICOLOGY AND PHARMACOLOGY, 2010, 58 (02) : 243 - 251
  • [29] Prediction of First-in-Human Dose of Chimeric Antigen Receptor-T (CAR-T) Cells from Mice
    Mahmood, Iftekhar
    EUROPEAN JOURNAL OF DRUG METABOLISM AND PHARMACOKINETICS, 2024, 49 (06) : 715 - 722
  • [30] First-in-human dose escalation of VLP Peanut in healthy subjects - Preliminary results
    De Kam, P. -J
    Shreffler, W.
    Lacasse, M.
    Krebs, M.
    Kramer, M. F.
    Hewings, S.
    Layhadi, J. A.
    Shamji, M. H.
    Skinner, M. A.
    ALLERGOLOGIE, 2024, 47 (09)